Printer Friendly

ALAMAR BIOSCIENCES PRODUCES FIRST NON-TOXIC IN VITRO INDICATOR DYE -- EXPECTED TO SIGNIFICANTLY REDUCE TOXICITY TESTING ON ANIMALS

 SACRAMENTO, Calif., Nov. 24 ~PRNewswire~ -- Alamar Biosciences Inc. (NASDAQ: ALMR), a developer, manufacturer and marketer of in vitro (outside the body) diagnostic testing products, has produced a non-toxic indicator dye for use in in vitro testing of pharmaceuticals, cosmetics, household cleaners and personal hygiene products for their potential toxic or irritant effect. Company officials believe the product, alamar Blue(TM) will significantly reduce the practice of toxicity testing on animals because it's easy to use, cost-effective and is harmless to humans, cells and the environment.
 Alamar's chief executive officer, Kenneth D. Miller, said, "In vitro testing is being adopted by manufacturers and testing laboratories as the most politically correct way to ensure consumers of the safety of their products. Alamar Blue takes in vitro testing the next step by being the first non-toxic test of its kind.
 "We expect alamar Blue to replace MTT, currently the most widely used reagent in in vitro toxicity tests, because of the many advantages alamar Blue has over MTT. Aside from being non-toxic, alamar Blue is water-soluble, cost-effective and provides flexible data gathering by colorimetric and fluorometric readings. It also has substantial labor saving advantages, which means the product lends itself well to automation for large screening programs. MTT, on the other hand, is highly toxic to users and cells, soluble only using hazardous chemicals, generates toxic organic wastes, uses colorimetric readings only and has far more extraction steps," continued Miller.
 According to Miller, alamar Blue was introduced in October and orders have already been received. "We expect to begin mass marketing the product shortly primarily through catalogs. Distribution through catalogs will introduce the product to both the domestic and international markets.
 "Aside from alamar Blue's extensive applications in biotechnology research, it also has applications in cytotoxicity, replacing protocols for cell analysis that utilize hazardous chemicals," he said. The research market includes universities, biotech R&D firms, pharmaceutical companies and health care institutions.
 Alamar Blue marks the company's first entrance into the toxicity, chemotherapy-resistance and anti-viral sensitivity testing markets. According to Alamar's executive vice president, Dr. Rebecca Fields, "Success of the product in toxicity tests will open doors of opportunity in chemo and anti-viral markets." Dr. Fields is the company's co-founder and chief scientific officer.
 Formed in 1988, Alamar Biosciences Inc. recently completed its initial public offering and is traded on NASDAQ under the symbol ALMR. The company develops, manufactures and markets in vitro diagnostic testing products for hospitals, reference laboratories and other health care providers. The company recently completed the development of proprietary disposable test kits, designed to diagnose the most effective type and dosage of antibiotics and identification in cases involving bacterial infection.
 -0- 11~24~92
 ~CONTACT: Kenneth D. Miller or Mark Santor of Alamar Biosciences, 916-567-3475; or Elizabeth Truax of The Financial Relations Board, 415-986-1591, for Alamar Biosciences~
 (ALMR)


CO: Alamar Biosciences Inc. ST: California IN: MTC SU: PDT

SG-GT -- SF002 -- 0881 11~24~92 08:30 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 24, 1992
Words:488
Previous Article:UNIVAR COMMENTS ON ANTICIPATED EARNINGS
Next Article:APPLE ANNOUNCES UPDATE TO MACTCP SOFTWARE
Topics:


Related Articles
ALAMAR BIOSCIENCES REPORTS YEAR-END RESULTS
ALAMAR BIOSCIENCES REPORTS FIRST QUARTER EARNINGS
ALAMAR BIOSCIENCES ANNOUNCES UNIT SPLIT, COMMON SHARES AND WARRANTS AVAILABLE FOR PURCHASE
ALAMAR BIOSCIENCES ADDS 3NET SOFTWARE TO GROWING PRODUCT LINE
ALAMAR BIOSCIENCES SIGNS DISTRIBUTION AGREEMENT FOR JAPAN
ALAMAR BIOSCIENCES ANNOUNCES PRIVATE FINANCINGS
ALAMAR BIOSCIENCES ANNOUNCES ADDITIONAL DISTRIBUTION INTO INTERNATIONAL BIOTECHNOLOGY MARKETS
ALAMAR BIOSCIENCES ANNOUNCES PROPOSED PRIVATE PLACEMENT
ALAMAR BIOSCIENCES REACHES AGREEMENT IN PRINCIPLE WITH SCHERER HEALTHCARE
ALAMAR BIOSCIENCES ANNOUNCES CUTBACKS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters